The FDA has accepted for Priority Review the NDA for vatiquinone for the treatment of children and adults living with Friedreich ataxia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback